|
|
| |
 |
| |
|
| |
Le Buanec H, Paturance S, Couillin I, Schnyder-Candrian S, Larcier P, Ryffel B, Bizzini B, Bensussan A, Burny A, Gallo R, Zagury D, Peltre G.
Control of allergic reactions in mice by an active anti-murine IL-4 immunizationVaccine. 2007 Oct 10;25(41):7206-16
|
| |
|
| |
Neovacs, a biotech company pioneering the development of anticytokine
and anti-viral regulation protein therapeutic vaccines for the treatment of certain cancers and
inflammatory diseases, today announced a major €13 million share capital increase with the Novartis Venture
Fund as the lead investor. Truffle Capital, an investor and majority shareholder since 2003, has reinvested €4
million in Neovacs.
The Novartis Venture Fund and Truffle Capital are likely to invite one or two additional
investors onboard in the coming months.
|
| |
|
| |
Neovacs and Inserm units U543 & U764 present the preclinical proof-of-concept of "IFN-alpha Kinoid" anti-IFN-alpha vaccine in a NZB/NZW F1 lupus prone mice model.
Active immunization with IFNα Kinoid prevents the development of Systemic Lupus Erythematosus in an IFNα-induced murine model of lupus disease.
|
| |
|
| |
Neovacs, a biotech company pioneering the
development of anti-cytokine and anti-viral regulation protein therapeutic vaccines,
announces the publication of an article on anti-VEGF kinoid vaccination in the
February 20 edition of the prestigious journal PNAS (the Proceedings of the National
Academy of Sciences of the USA). The authors demonstrate that active immunization
against VEGF was effective in several solid tumor models. This vaccine represents a
new therapeutic strategy in the treatment of malignant tumors by inhibiting their
neovascularization.
|
| |
 |
| |
Tumor growth depends on blood supply, requiring the development
of new vessels, and vascular endothelial growth factor
(VEGF) plays a central role in neoangiogenic processes. For this
reason, VEGF represents a target for the development of new
therapeutic antiangiogenic molecules. Clinical trials using anti-
VEGF mAbs such as bevacizumab have validated the efficacy of this
therapeutic approach but have also revealed adverse effects.
|
| |
|
| |
Néovacs, a biotech company pioneering the
development of anti-cytokine and anti-viral regulation protein therapeutic vaccines,
announces the publication of an article on anti-TNF-alpha therapeutic vaccination in
the December 21st edition of the prestigious journal PNAS (the Proceedings of the
National Academy of Sciences of the USA). The research shows that active
immunization against an endogenous cytokine may be a feasible approach in treating
pathologies associated with high TNF-alpha production, such as rheumatoid arthritis,
Crohn's disease, psoriasis and cachexia.
|
| |
 |
| |
TNF-alpha kinoid vaccination-induced neutralizing
antibodies to TNF-alpha protect mice from autologous
TNF-alpha-driven chronic and acute inflammation.
The proinflammatory cytokine TNF-alpha is a potent mediator of septic
shock and a therapeutic target for chronic inflammatory pathologies
including rheumatoid arthritis and Crohn’s disease.
As an
alternative to anti-human TNF-alpha (hTNF-alpha) mAbs and other hTNF-alpha
blocker approved drugs, we developed an active anti-hTNF-alpha immunotherapy,
based on a vaccine comprised of a keyhole limpet
hemocyanin-hTNF-alpha heterocomplex immunogen (hTNF-alpha kinoid)
adjuvanted in incomplete Freund’s adjuvant.
|
| |
|
| |
Neovacs,
a leading biotechnology company developing anti-cytokine and
anti-viral regulatory protein vaccines, today announced the
achievement of its first milestone under a license and equity
agreement signed with the Debiopharm Group (Debiopharm) for
the development of TNF (tumor necrosis factor) alpha Kinoid®
for the treatment of wasting syndromes such as cancer cachexia
and autoimmune diseases. This milestone triggers an undisclosed
payment by Debiopharm to Neovacs. |
 |
|
| |
Neovacs today announced the appointment of Guy-Charles Fanneau
de La Horie as its new Chief Executive Officer. Mr. Fanneau
de La Horie replaces Alain Huriez MD.
|
| |
|
|
Neovacs
is pleased to announce that it has been selected as one of the
100 companies driving the future of technology in the EMEA region
by Red Herring in its prestigious “Red Herring100 Europe”
listing. The company will present at the Venture Market Europe
2006 conference on May 10 at 5:30 p.m.
(Hotel Westin Castiglione, Paris).
|
| |
|
| |
Debiopharm S.A., the independent drug development company
specialising in oncology, endocrinology and niche products,
along with its wholly owned investment affiliate, Debioinnovation,
and Neovacs S.A., a French biotechnology company specializing
in the development of proprietary anti-cytokine immunogens,
today announced the signature of a license and equity agreement
for the development of a TNF (tumour necrosis factor) alpha
kinoid® and its related technology programmes.
|
|
|
| |
Neovacs,
biotechnology firm and leader in antibody therapies, has just
named Jean-Jacques Bertrand as its Chairman. “I am proud
to pass the baton to Jean-Jacques Bertrand, former Chairman
of Aventis Pasteur and member of the “CEO Circle”
of Truffle Venture” declared Dr Philippe Pouletty, previous
Chairman of Neovacs who remains one of its directors.
|
| |
|
| |
Neovacs, a world-leading company in the field of anticytokine
and anti-viral active immunization, is pleased to announce
the appointment of Patrick Larcier, Pharm.D., MBA, as Vice-President,
Drug Development.
This new appointment takes place at a time when Neovacs is
accelerating the preclinical and clinical development of several
products.
|
| |
 |
| |
Neovacs, a French biotechnology company leader in therapeutic
polyclonal antibodies, receives the IVCS prize in the Life
Sciences category. The 8 th IVCS rewarded 4 companies in the
following strategic fields: Life Sciences, Energy, Microelectronics,
Information Technology and Software and Multimedia. The IVCS
is one of the key European conferences related to the financing
of European most innovative companies...
|
| |
 |
| |
Neovacs, leader in the next generation of antibody therapies,
today announced that it has raised €1.5 million and simultaneously
has obtained a €1.2 million grant. Parisbased Truffle Venture
FCPR and Europe Innovation FCPI, current Neovacs investors,
invested an additional €1.5 million in convertible bonds.
At the same time Neovacs was granted €1.2 million from
ANVAR, the French Agency for Innovation, for the development
of Neovacs’ anti-TNF program. Truffle Venture thus reaffirms
... |
| |
 |
| |
Neovacs, a world-leading company in the field of anti-cytokine
and anti-viral active immunization, is pleased to announce
the appointments of Patrick Larcier, Pharm.D., MBA, as Director,
Clinical Development & Regulatory Affairs, and Thierry
Villette, Ph.D. Chem., MBA, as Director, Business Development
& Pharmaceutical Affairs. These new appointments take
place at a time when Neovacs ...
|
| |
 |
| |
Neovacs, the leader in the development of novel anticytokine
and anti viral antibody therapies today announced the appointment
of Alain Huriez, M.D., as CEO. Alain brings nearly 15 years
of international executive and operational experience in the
pharmaceutical and biotechnology industry, as well as a solid
track record in funding, advising, and participating in the
growth of early-stage companies. Alain will be responsible
...
|
| |
 |
| |
Neovacs, a spin-off biotechnology company from Pierre and
Marie Curie University and the leader in the development of
vaccine-induced polyclonal antibody therapies, today announced
that it has raised 3.5 million Euros in new financing. Paris-based
Truffle Venture FCPR and Europe Innovation FCPI made the investment,
and now own 51% of Neovacs. Neovacs currently develops several
promising product candidates based on its cytokine vaccine
and viral vaccine patented technologies. Neovacs therapeutic
AIDS vaccine is already in human clinical trials in collaboration
with Aventis Pasteur. Aventis Pasteur, the vaccines business
of Aventis, is one of the world’s largest vaccine producers.
Neovacs also acquired from ...
|
 |
|
|
